Report: Global biosimilars market could approach $2B in 5 years

11/19/2013 | Drug Store News

A MarketsandMarkets report forecasts that the global biosimilars market will be worth $1.95 billion by 2018. Insulin, filgrastim and other recombinant protein products hold the biggest share of the market, but monoclonal antibodies are expected to be the fastest-growing segment. The Asia-Pacific region, which accounts for 29% of the global market, is forecast to grow the fastest, while the U.S. is waiting on the FDA to write regulations establishing a pathway for biosimilar reviews.

View Full Article in:

Drug Store News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY